Press Releases
  Date Title View
Jun 7, 2010
WALTHAM, MA, June 7, 2010 – ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the presentation of the first clinical data for the Company’s IMGN388 anticancer compound at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in ...
PDF
Jun 5, 2010
WALTHAM, Mass., Jun 05, 2010 (BUSINESS WIRE) --ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the presentation of clinical data from a Phase Ib/II trial conducted by Roche and Genentech to investigate the safety and preliminary efficacy of trastuzumab-DM1 (T-DM1) used i...
PDF
Jun 3, 2010
WALTHAM, Mass., Jun 03, 2010 (BUSINESS WIRE) --ImmunoGen, Inc. (Nasdaq: IMGN) announced today that Daniel Junius, President and CEO, will present at two investor conferences next week. These presentations will be webcast live and can be accessed through the "Investor Information" section of the Company's website, www.immunogen.com. An archive of...
PDF
May 24, 2010
WALTHAM, Mass., May 24, 2010 (BUSINESS WIRE) --ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that there will be several clinical data presentations for compounds utilizing the Company's Targeted Antibody Payload (TAP) technology at the 2...
PDF
May 10, 2010
WALTHAM, Mass., May 10, 2010 (BUSINESS WIRE) --ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase 1,350,000 shares of common stock at a public o...
PDF
May 7, 2010
WALTHAM, Mass., May 07, 2010 (BUSINESS WIRE) --ImmunoGen, Inc. (Nasdaq: IMGN) is scheduled to present at the Bank of America Merrill Lynch Health Care Conference at 1:40 pm ET on May 13, 2010. The Conference is being held at the Grand Hyatt New York. ImmunoGen's presentation will be webcast live and can be...
PDF
May 6, 2010
WALTHAM, Mass., May 06, 2010 (BUSINESS WIRE) --ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that it has priced a public offering of 9,000,000 shares of its common stock at a price of $8.00 per share. Net proceeds, after underwriting discounts and commissions and expen...
PDF
May 5, 2010
WALTHAM, Mass., May 05, 2010 (BUSINESS WIRE) --ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that it intends to offer, subject to market and other conditions, 8,500,000 shares of its common stock in an underwritten public offering. ImmunoGen ...
PDF
Apr 29, 2010
WALTHAM, Mass., Apr 29, 2010 (BUSINESS WIRE) --ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced financial results for the three-month period ended March 31, 2010 - the third quarter of the Company's 2010 ...
PDF
Apr 22, 2010
WALTHAM, Mass., Apr 22, 2010 (BUSINESS WIRE) --ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted anticancer products, today announced that will host a conference call at 4:30 pm ET on Thursday, April 29, 2010 to discuss the Company's financial results for the three-month period ended March 31, 2010 - the third quarter...
PDF
Apr 15, 2010
WALTHAM, Mass., Apr 15, 2010 (BUSINESS WIRE) --ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products, today announced that Roche has provided a favorable update related to its plans to apply for marketing approval of trastuzumab-DM1 (T-DM1) in the US. T-DM1 comprises ImmunoGen's DM1 cancer-ce...
PDF
Mar 18, 2010
WALTHAM, Mass., Mar 18, 2010 (BUSINESS WIRE) -- ImmunoGen, Inc. (Nasdaq: IMGN) is scheduled to present at the 2010 Barclays Capital Global Healthcare Conference at 3:45 pm ET on March 24, 2010. The Conference is being held at the Loews Miami Beach Hotel in Miami Beach, Florida. ImmunoGen's presentation wil...
PDF
Mar 8, 2010
WALTHAM, Mass., Mar 08, 2010 (BUSINESS WIRE) -- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its IMGN901 compound ...
PDF
Mar 1, 2010
WALTHAM, Mass., Mar 01, 2010 (BUSINESS WIRE) -- ImmunoGen, Inc. (Nasdaq: IMGN) announced today that management will participate in two upcoming investor conferences with live webcasts. RBC Capital Markets Healthcare Conference, New York Palace Hotel, New York, NY Gregory Perry, Senior Vice President and Chief Financial Office...
PDF
Feb 3, 2010
WALTHAM, Mass., Feb 03, 2010 (BUSINESS WIRE) -- ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceuticals company that develops targeted anticancer therapeutics using its Targeted Antibody Payload (TAP) technology, invites investors, journalists and the general public to listen to a live webcast of the Company's investment community meeting on Februa...
PDF
Feb 2, 2010
WALTHAM, Mass., Feb 02, 2010 (BUSINESS WIRE) -- ImmunoGen, Inc. (Nasdaq: IMGN) is scheduled to present at the 12th Annual BIO CEO & Investor Conference at 2:30 pm ET on February 9, 2010. The Conference is being held at the Waldorf=Astoria hotel in New York City. ImmunoGen's presentation will be webcast...
PDF
Jan 28, 2010
WALTHAM, Mass., Jan 28, 2010 (BUSINESS WIRE) -- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced financial results for the three-month period ended December 31, 2009 - the ...
PDF
Jan 21, 2010
WALTHAM, Mass., Jan 21, 2010 (BUSINESS WIRE) -- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products, today announced that will host a conference call at 4:30 p.m. ET on Thursday, January 28, 2010 to discuss the Company's financial results for the three-month period ended December 31, 2009 - the seco...
PDF
Jan 6, 2010
WALTHAM, Mass., Jan 06, 2010 (BUSINESS WIRE) -- ImmunoGen, Inc. (Nasdaq: IMGN) is scheduled to present at the 28th Annual J.P. Morgan Healthcare Conference at 9:30 am PST on January 14, 2010. The Conference is being held at the Westin St. Francis hotel in San Francisco, CA. ImmunoGen's presentation will be webcast live and can be accessed throug...
PDF
FirstPrevious ...
13

You are now leaving this website. If you would like to continue, click Continue.
CancelContinue